NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Abramson Cancer Center at Penn Medicine
Conditions: Lung Cancer, Medication Adherence, Symptoms and Signs
Interventions: Conversational Agent/Chatbot, Usual Care
Countries: United States
The objective of this project is to identify effective strategies to help patients with lung cancer manage side effects and achieve optimal adherence to oral targeted therapies. To achieve this objective, we will evaluate the effect of a novel, bidirectional conversational agent, compared to usual care, on adherence to oral targeted therapies using a two-arm randomized controlled trial, and explore how multilevel factors impact the acceptability and effectiveness of this strategy by collecting qualitative and quantitative data from clinicians and patients.
Sex: ALL
Age: 18 Years to —
Healthy volunteers: No
Study type: INTERVENTIONAL
Inclusion Criteria: * Adult patient (age \> 18 years) with NSCLC at UPHS who is receiving one of the following nine oral therapies: afatinib, erlotinib, dacomitinib, gefitinib, osimertinib, alectinib, brigatinib, crizotinib, or lorlatinib. * Patient possession of a mobile device that can send/receive SMS texts * Ability to respond to questions and engage with "Penny" in English * Ability to provide informed consent to participate in the study * Approval from the patient's medical oncologist to be approached Exclusion Criteria: * Inability to respond to questions and engage with "Penny" in English * Inability or unwillingness to provide informed consent to participate in the study * Inability to engage with SMS text-messaging platform * Concurrent enrollment in a therapeutic clinical trial * Taking more than one oral targeted therapy or concurrent chemotherapy during the study window * Lack of approval from the patient's oncologist
- Philadelphia, Pennsylvania, United States